CYTOPHAGE TECHNOLOGIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.39 CAD | 0.00% |
|
-11.36% | -44.65% |
| 27/05 | Cytophage Technologies Ltd. Strengthens Board of Directors | CI |
| 30/04 | Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.53Cr 2.09Cr 127.7Cr |
|---|---|---|---|---|---|
| Net income 2022 | -30L -41.08L -25Cr | Net income 2023 | -40L -54.78L -33Cr | EV / Sales 2022 | - |
| Net cash position 2022 | 21.38L 29.28L 18Cr | Net Debt 2023 | 17.55L 24.03L 15Cr | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.07
x | P/E ratio 2023 |
-6.45
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -11.36% | ||
| Current month | -20.41% | ||
| 1 month | -23.53% | ||
| 3 months | -19.59% | ||
| 6 months | -44.65% | ||
| Current year | -44.65% |
1 week
0.36
0.44
1 month
0.330.52
Current year
0.310.76
1 year
0.310.76
3 years
0.271.12
5 years
0.271.12
10 years
0.271.12
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Theriault
CEO | Chief Executive Officer | - | 08/02 |
Julius Kalcevich
DFI | Director of Finance/CFO | 49 | 08/02 |
Heather Medwick
COO | Chief Operating Officer | - | 08/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harold Wolkin
CHM | Chairman | 72 | - |
Andrew Hurley
BRD | Director/Board Member | - | - |
Steven Theriault
CEO | Chief Executive Officer | - | 08/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 0.39 | 0.00% | 10,500 |
| 20/24/20 | 0.39 | 0.00% | 95,500 |
| 19/24/19 | 0.39 | -3.70% | 9,000 |
| 18/24/18 | 0.405 | -4.71% | 16,000 |
| 17/24/17 | 0.425 | -3.41% | 4,500 |
Delayed Quote Toronto S.E., June 22, 2024 at 01:29 am IST
More quotes
Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.
Sector
Pharmaceuticals
Calendar
26/06/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -44.65% | 1.53Cr | |
| +51.63% | 80TCr | |
| +41.51% | 63TCr | |
| -5.10% | 36TCr | |
| +19.90% | 33TCr | |
| +9.95% | 30TCr | |
| +17.66% | 24TCr | |
| +3.39% | 23TCr | |
| +10.75% | 21TCr | |
| +6.99% | 17TCr |
- Stock Market
- Equities
- CYTO Stock
